NCT00427596View on ClinicalTrials.gov

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Overactive Bladder

Interventions

DRUG

Solabegron

Trial Locations (1)

14209

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00427596 - A Two-Part Study to Determine: Best Medication Formulation and Food Effect | Biotech Hunter | Biotech Hunter